Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 + QL1706 as first-line therapy for HER2-overexpressing NSCLC
ChiCTR2500114106Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab rezetecan and QL1706 in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: 12-month Progression-Free Survival Rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
trastuzumab rezetecanQL1706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500114106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114106.